Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4364016 | 0.88 | ALDH1A1 (0.43) | TK1ALDH1A1POLB | |
| SCHEMBL9744721 | 0.88 | LMNA (0.43) | TK1LMNA | |
| SCHEMBL6258952 | 0.88 | TK1 (0.43) | TK1BLM | |
| SCHEMBL8176114 | 0.87 | TK1 (0.33) | TK1DHFR | |
| SCHEMBL8167928 | 0.85 | TK2 (0.37) | TK1TK2 | |
| SCHEMBL9803727 | 0.84 | TK1 (0.36) | TK1TK2 | |
| SCHEMBL4366634 | 0.81 | SLC28A1 (0.36) | — | |
| SCHEMBL4064057 | 0.81 | TK1 (0.38) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL551408 | 0.80 | TK1 (0.49) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL10385764 | 0.80 | TK1 (0.41) | TK1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4707286-A1 | HIGHLY LIPID-SOLUBLE NUCLEOTIDE BUILDING BLOCK FOR OLIGONUCLEOTIDE SYNTHESIS, AND SYNTHESIS OF OLIGONUCLEOTIDES USING SAME | Natias Inc. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-20250171482-A1 | DEACYLATION OF CARBOHYDRATE COMPOUNDS | UNIVERSITY OF SOUTH ALABAMA | 2025-05-29 | — | — | US | disclosed |
| WO-2024228396-A1 | HIGHLY LIPID-SOLUBLE NUCLEOTIDE BUILDING BLOCK FOR OLIGONUCLEOTIDE SYNTHESIS, AND SYNTHESIS OF OLIGONUCLEOTIDES USING SAME | 株式会社ナティアス | 2024-11-07 | — | — | WO | disclosed |
| CN-118632856-A | By bringing the carbohydrate deacylation of the substance | 益力舒健康公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-2356246-B1 | Biocatalytic preparation of 5-methyluridine | CSIR (ZA) | 2012-08-22 | — | — | EP | disclosed |
| EP-2356246-A1 | BIOCATALYTIC PREPARATION OF NUCLEOSIDES | CSIR (ZA) | 2011-08-17 | — | — | EP | disclosed |
| EP-1348712-B1 | Processes and intermediates in the synthesis of L-thymidine | MITSUI CHEMICALS INC (JP) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010055369-A1 | BIOCATALYTIC PREPARATION OF NUCLEOSIDES | CSIR (ZA) | 2010-05-20 | — | — | WO | disclosed |
| US-7125983-B2 | L-nucleic acid derivatives and process for the synthesis thereof | MITSUI CHEMICALS, INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20040063926-A1 | L-nucleic acid derivative and processes for the synthesis thereof | MITSUI CHEMICALS, INC. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1348712-A1 | L-NUCLEIC ACID DERIVATIVES AND PROCESSES FOR THE SYNTHESIS THEREOF | Mitsui Chemicals, Inc. (JP) | 2003-10-01 | — | — | EP | disclosed |
| EP-1041159-A2 | Method, oligonucleotides suitable for the degradation of in vitro synthesized nucleic acid molecules | MIRA Diagnostika GmbH (DE) | 2000-10-04 | — | — | EP | disclosed |
| US-5175273-A | Pyridinone or pyrimidinone nucleoside bases containing fused aromatic polycyclic rings | GENENTECH, INC. (US) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171482-A1 | DEACYLATION OF CARBOHYDRATE COMPOUNDS | FUT5, DDOST, TREH | TK1 3510/4885DHFR 1893/4885TK2 3434/4885 |
| US-20040063926-A1 | L-nucleic acid derivative and processes for the synthesis thereof | TYMS, RNGTT, DTYMK | TK1 23/4885DHFR 26/4885TK2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.